Invention Grant
- Patent Title: Use of hydrogen sulfide synthesis inhibitors for cancer therapy
-
Application No.: US14967649Application Date: 2015-12-14
-
Publication No.: US10335382B2Publication Date: 2019-07-02
- Inventor: Mark Hellmich , Jia Zhou , Csaba Szabo
- Applicant: Mark Hellmich , Jia Zhou , Csaba Szabo
- Applicant Address: US TX Austin
- Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: US TX Austin
- Agency: Norton Rose Fulbright US LLP
- Main IPC: A61K31/195
- IPC: A61K31/195 ; A61K31/325 ; A61K31/22 ; A61K31/222 ; C12N15/113 ; A61K31/221 ; A61K31/27 ; A61K31/7105 ; A61K45/06 ; C07C291/04
Abstract:
In certain aspects the methods comprise administering an inhibitor of hydrogen sulfide biosynthesis, a cystathionine-β-synthase (CBS) inhibitor, or a hydrogen sulfide neutralizing agent to a patient having a cancer associated with elevated production of hydrogen sulfide.
Public/Granted literature
- US20160095831A1 USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY Public/Granted day:2016-04-07
Information query
